Management of Hypertension in Obese Patients

Introduction to Beta-Blockers

The American Heart Association recommends that beta-blockers as a class should be avoided as first-line antihypertensive treatment in patients with overweight or obesity due to several metabolic concerns 1, 2, 3
Beta-blockers can have adverse metabolic effects, including potential negative effects on lipids and insulin sensitivity 1, 2, 3

The American College of Cardiology suggests that if a beta-blocker is medically required in an obese patient, prioritize vasodilating beta-blockers over bisoprolol 1, 2, 3
Carvedilol or nebivolol are recommended when beta-blockers are required for conditions such as coronary artery disease, heart failure, or arrhythmias 1, 2, 3
Carvedilol has an advantage in heart failure, being more effective in reducing blood pressure than metoprolol succinate or bisoprolol due to its combined α1-β1-β2-blocking properties 4

The European Society of Cardiology recommends that weight-neutral antihypertensive options should be prioritized, such as ACE inhibitors or ARBs, which are particularly desirable for obese patients as angiotensin is overexpressed in obesity 1, 2, 3
Calcium channel blockers are also a weight-neutral option 1, 2, 3
Thiazide diuretics should be avoided due to dose-related side effects, including dyslipidemia and insulin resistance 1, 2, 3